Pfizer developed fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor for the treatment of rheumatoid arthritis. The drug successfully completed the phase II clinical trial; however, further study of the drug was discontinued.

AZD-2461 is an oral inhibitor of PARP-1, which was developed by AstraZeneca as a potential anti-cancer medicine. The drug was tested in phase I clinical patients against solid tumosr, but its development was discontinued.

Oprozomib (PR-047) is an orally bioavailable derivative of carfilzomib, with similar biological activity, i.e. inhibition of the chymotrypsin-like activity of the proteasome. It inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Oprozomib (PR-047) is being investigated for the treatment of hematologic malignancies, specifically, multiple myeloma, with Phase I/II trial ongoing.

AZD4877 was developed by AstraZeneca as a potent inhibitor of the mitotic spindle kinesin, Eg5. AZD4877 participated in clinical trials phase I/II for patients with acute myeloid leukemia, the study was terminated due to lack of efficacy. In addition, the drug was studied in Phase II in patients with previously treated advanced urothelial cancer. However, limited clinical efficacy stops the further development of AZD4877 in urothelial cancer.

GSK-1614235 (mizagliflozin) is a sodium glucose co-transporter type 1 (SGLT1) inhibitor that has been investigated for treatment in type 2 diabetes. It is thought to suppress glucose absorption from the intestine in a way that is different from conventional type 2 diabetes drugs, thereby improving postprandial hyperglycemia. Phase 1 studies have been completed.

Icopezil (previously known as CP-118,954) was developed as a selective acetylcholinesterase inhibitor for the treatment of cognitive disorders. Phase II trials of icopezil were underway in Japan and in the USA for the treatment of patients with Alzheimer's disease. However, Pfizer has discontinued these studies.

Propoxycarbazone-Sodium (also known as BAY MKH 6561) is asulfonylaminocarbonyltriazolinone derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as herbicide Propoxycarbazone inhibits acetolactate synthase (ALS), and has selectivity on spring, winter, and durum varieties. The spectrum of control includes several species of monocot and dicot weeds at the application rates of 30 to 45 g/ha. Bromus control is the primary target since existing herbicides have limited timing, selectivity, and use patterns which reduce usefulness. Propoxycarbazone applied postemergence between the 1- to 2-leaf stage and shoot elongation has provided economic control of the following Bromus species: B. tectorum, B. secalinus, B. mollis, B. rigidus, and B. japonicus. Side effects, and sometimes control, was also noted on Aegilops tauschii for which there is no selective control outside genetically altered wheat cultivars. Broadleaf control was obtained primarily on the mustard family, including species in the genera Sisymbrium, Brassica, Descurainia, Chorispora, Camelina, Capsella, and Thlaspi. Propoxycarbazone provides control for adequate weed spectrum, however, considerations of resistance management, difficult and diverse weed pressure, and extended growing seasons will sometimes necessitate the use of sequential herbicides or mix partners.